Glioma

116 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms, Neoplasms, Germ Cell and Embryonal

Narrower: Astrocytoma 52, Glioblastoma 44, Gliosarcoma 8, Medulloblastoma 8, Oligodendroglioma 2

Treatments and conditions

Glioma
Treatment and conditionWhere it standsTrials
[11C]AZ1419 3391 + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
[11C]AZ1419 3391 + Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Accelerated Hypofractionated Radiation Therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Allogeneic genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for glioblastomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for gliosarcomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
autologous dendritic cells pulsed with tumor lysate antigen Vaccine + Laboratory Biomarker Analysis + Quality-of-Life Assessment + Questionnaire Administration + NIVOLUMAB for oligodendrogliomaTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Autologous genetically modified gamma-delta T cells for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Biospecimen Collection + EFINEPTAKIN ALFA + PEMBROLIZUMAB for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Multigated Acquisition Scan + Radiologic Examination + OSIMERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Radiologic Examination + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Laboratory Biomarker Analysis + Radiologic Examination + PERTUZUMAB + TRASTUZUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brain surgery + SRS + RETIFANLIMAB + RAGIFILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CTX-471 + Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ADAVOSERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Binimetinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + CAPIVASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Crizotinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Dasatinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + DEFACTINIB + DEFACTINIB HYDROCHLORIDE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Fexagratinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + GSK-2636771 for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + IPATASERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + NIVOLUMAB + RELATLIMAB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Palbociclib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + SAPANISERTIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TASELISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + Trametinib + Dabrafenib Mesylate + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + TRASTUZUMAB + TRASTUZUMAB EMTANSINE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ULIXERTINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dabrafenib, trametinib, nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-escalated radiation therapy for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Accelerated Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dose-intensified Photon Beam Radiation Therapy for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Educational and Media Intervention for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eflornithine for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
External Beam Radiation Therapy + Laboratory Biomarker Analysis + Radiation Therapy + Therapeutic Conventional Surgery + PEMBROLIZUMAB + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Fluzoparib with Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Hypofractionated re-irradiation + MANNITOL + Cetuximab for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Caelyx for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IA Carboplatin + IA Etoposide Phosphate for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IDH1 peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1-vac for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
IDH1R132H peptide vaccine + AVELUMAB for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Idroxioleate Sodium for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ipatasertib + atezolizumab for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irradiation + Surgical resection + PEGFILGRASTIM + Vincristine + ETOPOSIDE + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivoximab 20 mg/kg, ivgtt, Q4W + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
JBI-778 for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
JK-1201I + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + SARGRAMOSTIM + SVN53-67/M57-KLH PEPTIDE VACCINE + INCOMPLETE FREUND'S ADJUVANT + Temozolomide for gliosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low-dose Radiotherapy + SINTILIMAB for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
M032 + PEMBROLIZUMAB for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + AFATINIB + AFATINIB DIMALEATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Sunitinib Malate for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Echocardiography Test + Laboratory Biomarker Analysis + Radionuclide Imaging + Vismodegib for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + ERDAFITINIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Biospecimen Collection + Computed Tomography + Cytology Specimen Collection Procedure + Laboratory Biomarker Analysis + LAROTRECTINIB + LAROTRECTINIB SULFATE for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biopsy Procedure + Computed Tomography + Cytology Specimen Collection Procedure + COPANLISIB HYDROCHLORIDE + COPANLISIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Lumbar Puncture + Radiation Therapy + Dabrafenib Mesylate + TRAMETINIB DIMETHYL SULFOXIDE for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Laboratory Biomarker Analysis + Radiation Therapy + Vincristine + Lomustine + Cyclophosphamide + CISPLATIN + Vincristine Sulfate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Maximal surgical resection + Radical radiotherapy + Stupp regimen (oral temozolomide) + THIOTEPA for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin hydrochloride for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for glioblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ommaya/VPS + Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onfekafusp alfa for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Optune System + PEMBROLIZUMAB + Temozolomide for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Datopotamab Deruxtecan for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Palacaparib + Temozolomide for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Perillyl alcohol for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + Metformin for medulloblastomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiodynamic therapy + AMINOLEVULINIC ACID HYDROCHLORIDE for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab govitecan for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Selinexor for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonication for opening of blood-brain barrier + Carboplatin + NAB-PACLITAXEL for gliosarcomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Srs + retifanlimab + ragifilimab for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Subventricular Zone radiation for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Surgical resection + PEGFILGRASTIM + Vincristine + TOPOTECAN + Cyclophosphamide + Carboplatin + FILGRASTIM + CISPLATIN + Methotrexate for medulloblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab + Temozolomide for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Temozolomide for glioblastomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Tovecimig for glioblastomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib + DABRAFENIB for gliomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trametinib and Nivolumab for gliomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TRASTUZUMAB DERUXTECAN + Palacaparib for astrocytomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vebreltinib for glioblastomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.